This Article Full Text Full Text (PDF) All Versions of this Article: 36/3/682    most recent 01.STR.0000155742.46437.65v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kleindorfer, D. Articles by Broderick, J. P. Search for Related Content PubMed PubMed Citation Articles by Kleindorfer, D. Articles by Broderick, J. P. Pubmed/NCBI databases Medline Plus Health Information Stroke Transient Ischemic Attack Related Collections Thrombolysis Acute Cerebral Infarction Emergency treatment of Stroke

(Stroke. 2005;36:682.)
© 2005 American Heart Association, Inc.

Special Reports

A Description of Canadian and United States Physician Reimbursement for Thrombolytic Therapy Administration in Acute Ischemic Stroke

Dawn Kleindorfer, MD; Michael D. Hill, MD, FRCPC; Daniel Woo, MD; Thomas Tomsick, MD; Arthur Pancioli, MD; Brett Kissela, MD; Andrew M. Demchuk, MD; David Losiewicz, BS; Edward Jauch, MD, MS; Alexander Schneider, MD; Andrew Ringer, MD; Daniel Kanter, MD Joseph P. Broderick, MD

From the Departments of Neurology (D.Kleindorfer, D.W., B.K., A.S., D. Kantner, J.P.B.), Radiology (T.T.), Emergency Medicine (A.P., E.J.), and Neurosurgery (A.R.), University of Cincinnati College of Medicine, Cincinnati, Ohio; the Department of Clinical Neuroscience (M.D.H., A.M.D.), University of Calgary, Calgary, AB, Canada; and University Neurology Inc (D.L.), Cincinnati, Ohio.

Correspondence to Dr Dawn Kleindorfer, Assistant Professor of Neurology, University of Cincinnati College of Medicine, 231 Albert Sabin Way ML0525, Cincinnati, OH 45267-0525. E-mail dawn.kleindorfer{at}uc.edu

Abstract

Background and Purpose— Acute ischemic stroke patients are infrequently treated with rtPA, despite its proven effectiveness. Poor physician reimbursement for acute stroke care is one possible explanation for the low frequency of use. We describe the physician reimbursement for thrombolytic therapy for the stroke team physicians serving the Greater Cincinnati/Northern Kentucky region (GCNK), and the Alberta region.

Methods— GCNK: billing logs were accessed for the study period of 7/01–12/02, and cross-matched to stroke call logs. University of Calgary (UC): treatment records of a single physician were reviewed from 4/02–3/04. A telephone survey of Canadian provinces was conducted regarding billing practices.

Results— GCNK: During the study period, 151 patients received rtPA. For treated pts. the average time spent was 2.6 hours, and average reimbursement received was $472 (of those with insurance). The highest reimbursement was received by billing critical care codes. Reimbursement for critical care was similar to or lower than common office procedures for neurologists. UC: during the study period, 131 patients received rtPA. Average reimbursement for rtPA treated patients was $340 US, not including on-call payments. Survey across Canada revealed many provinces with weekend/after hour premium stipends and on-call stipends.

Conclusions— Physician reimbursement for the evaluation and treatment of acute stroke, when compared with other diagnoses commonly treated by neurologists, is relatively low in both the U.S. and Canada. Health policy decision-makers in the US and Canada should be made aware of the importance of providing a more balanced plan to provide medical care to stroke patients.

Key Words: stroke, acute • stroke, ischemic • tissue plasminogen activator • thrombolytic therapy

This article has been cited by other articles:

				E. C. Leira, J. K. Pary, P. H. Davis, K. J. Grimsman, and H. P. Adams Jr Slow Progressive Acceptance of Intravenous Thrombolysis for Patients With Stroke by Rural Primary Care Physicians Arch Neurol, April 1, 2007; 64(4): 518 - 521. [Abstract] [Full Text] [PDF]

				B. M. Demaerschalk and D. L. Durocher How Diagnosis-Related Group 559 Will Change the US Medicare Cost Reimbursement Ratio for Stroke Centers Stroke, April 1, 2007; 38(4): 1309 - 1312. [Abstract] [Full Text] [PDF]

				K. Z. Bambauer, S. C. Johnston, D. E. Bambauer, and J. A. Zivin Reasons why few patients with acute stroke receive tissue plasminogen activator. Arch Neurol, May 1, 2006; 63(5): 661 - 664. [Abstract] [Full Text] [PDF]

				H. F. McGruder, J. B. Croft, and Z.-J. Zheng Characteristics of an "Ill-Defined" Diagnosis for Stroke: Opportunities for Improvement Stroke, March 1, 2006; 37(3): 781 - 789. [Abstract] [Full Text] [PDF]